A Novel Combination Therapy Using Rosuvastatin and <i>Lactobacillus</i> Combats Dextran Sodium Sulfate-Induced Colitis in High-Fat Diet-Fed Rats by Targeting the TXNIP/NLRP3 Interaction and Influencing Gut Microbiome Composition

A Novel Combination Therapy Using Rosuvastatin and <i>Lactobacillus</i> Combats Dextran Sodium Sulfate-Induced Colitis in High-Fat Diet-Fed Rats by Targeting the TXNIP/NLRP3 Interaction and Influencing Gut Microbiome Composition

Inflammasome targeting and controlling dysbiosis are promising therapeutic approaches to control ulcerative colitis. This report is the first to investigate the mechanisms underlying the coloprotective effects of rosuvastatin and <i>Lactobacillus</i> and their combined therapy on dextran...

Full description

Bibliographic Details
Main Authors: Sameh Saber, Eslam E. Abd El-Fattah, Galal Yahya, Naglaa A. Gobba, Abdalkareem Omar Maghmomeh, Ahmed E. Khodir, Ahmed A. E. Mourad, Ahmed S. Saad, Hager G. Mohammed, Nehal A. Nouh, Ahmed Shata, Noha A. Amin, Magdy Abou El-Rous, Samuel Girgis, Eman El-Ahwany, Eman M. Khalaf, Attalla F. El-Kott, Ahmed M. El-Baz
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceuticals
Subjects:
ulcerative colitis
NLRP3 inflammasome
rosuvastatin
<i>Lactobacillus</i>
gut microbiome
TXNIP
Online Access:https://www.mdpi.com/1424-8247/14/4/341

Internet

https://www.mdpi.com/1424-8247/14/4/341

Similar Items